Print page
Email page
Download PDF
« Previous Release | Next Release »
COLUMBIA, Md., Aug 11, 2008 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ: CLSN), a biotechnology, drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today reported that it would hold a conference call to discuss second quarter results at 11:00 a.m. Eastern Time on Monday, August 18, 2008. To participate in the call, interested parties may dial 877-604-2080 (U.S./Canada) or 706-902-1383 (International) and use Conference ID: #59454102 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the Internet at http://www.celsion.com.
The call will be archived for replay on August 18, 2008 at 2:00 P.M. and will remain available until Monday, August 25, 2008. The replay can be accessed at 800-642-1687 or 706-645-9291 using Conference ID: #59454102. The call will also be available on the Company's website, http://www.celsion.com for 30 days after 2:00 p.m. on Monday, August 18, 2008.
About Celsion:
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems.
Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion website at www.celsion.com.
SOURCE: Celsion Corporation
FD Ashton Partners Geoff Grande, 617-747-1721 Geoff.Grande@fdashtonpartners.com
Copyright Business Wire 2008
News Provided by COMTEX
